GlassScriptPhysician profile
Caterina Violi
NPI 1942395777
$6,442.01
in general payments reported to CMS, 2019-2025
29 companies · $693 in 2025
The $693 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,566 · 2020: $974 · 2021: $846 · 2022: $1,028 · 2023: $907 · 2024: $428 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,010 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.23 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,697.76 | 2019-2024 | Lo Loestrin Fe, Orilissa, Liletta |
| Mayne Pharma Commercial LLC | $794.29 | 2021-2025 | |
| Avion Pharmaceuticals | $606.38 | 2019-2022 | |
| Exeltis, USA INC. | $505.87 | 2019-2021 | |
| Exact Sciences Corporation | $413.85 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $345.87 | 2019-2020 | |
| Pfizer INC. | $266.32 | 2019-2025 | |
| Vertical Pharmaceuticals, LLC | $229.82 | 2019 | |
| Therapeuticsmd, INC. | $208.87 | 2019-2022 | |
| Medtronic Vascular, INC. | $197.28 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $159.19 | 2021-2025 | Vpriv |
| Myovant Sciences INC. | $154.61 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $131.53 | 2023-2024 | Myfembree |
| Agile Therapeutics, INC. | $88.21 | 2021-2022 | |
| Coopersurgical, INC. | $81.78 | 2019-2025 | Paragard T 380a |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $78.53 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Biogen, INC. | $73.20 | 2025 | Zurzuvae |
| Aspira Women'S Health INC | $69.53 | 2025 | Ova1 |
| Medtronic, INC. | $60.17 | 2021 | |
| Medicem INC. | $57.08 | 2020 | |
| Scynexis, INC. | $47.34 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.82 | 2019-2022 | |
| Roche Diagnostics Corporation | $23.63 | 2020 | |
| Abbott Laboratories | $20.79 | 2022 | |
| Hologic Sales and Service, LLC | $20.58 | 2022 | |
| Mission Pharmacal Company | $19.49 | 2023 | Citranatal |
| Evofem Biosciences, INC. | $18.69 | 2020 | |
| Astellas Pharma US INC | $16.90 | 2023 | Veozah |
| Channel Medsystems, INC. | $13.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caterina Violi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.